Wu M, et al. – In this study, researchers deliberated prostate cancer–targeting poly(lactide–co–glycolic acid) (PLGA) nanobubbles (NBs) modified using A10–3.2 aptamers targeted to prostate–specific membrane antigen (PSMA) and encapsulated paclitaxel (PTX). They successfully established an A10–3.2 aptamer and loaded PTX–PLGA multifunctional theranostic agent for the purpose of obtaining US images of prostate cancer and serving low–prevalence US–triggered therapy of prostate cancer that was likely to constitute a strategy for both prostate cancer imaging and chemotherapy.